(Reuters)-The U.S. drug regulatory agency approved Moderna Inc. to speed up the production of its COVID-19 vaccine by filling a single vial with up to 15 needles, while the United States relies on rapid immunization to prevent the spread of the deadly vaccine.
The U.S. Food and Drug Administration (FDA) also authorizes vaccinators to extract up to 1
Moderna said in a statement that its vaccine can now be packed in vials containing 11 or 15 doses, and it is expected to start shipping 15-dose vials in the next few weeks.
Peter Marks, director of the FDA’s Center for Biological Evaluation and Research, said: “Both revisions have had a positive impact on the supply of Moderna COVID-19 vaccine, which will help provide more vaccine doses to the community and make injections faster Put into use.”.
However, the regulatory agency also warned that without the correct syringe and needle, it may not be possible to extract more than 13 doses from Moderna’s 15-dose vials and more than 10 doses from the existing vials.
As of March 29, Moderna has provided 100 million doses of vaccine to the United States. Injections from Pfizer/BioNTech and Johnson & Johnson are the other two vaccines approved in the country.
With the increase in cases and the cancellation of the authorization of masks in several states, and the spread of infectious variants, the health authorities hope that the contract with the currently approved vaccine manufacturer will be sufficient to meet the needs of the entire population.
Anthony Fauci, a top US infectious disease doctor, told Reuters on Thursday that the country may not need AstraZeneca’s COVID-19 vaccine even if it has received US regulatory approval.
Reporting by Radhika Anilkumar and Shubham Kalia in Bangalore; Editing by Uttaresh.V and Simon Cameron-Moore